JRJun Ren

Jun Ren

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Ren has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells

    by Bo Ma, Hanfang Jiang, Jun Jia, Lijun Di, Guohong Song, Jing Yu, Yulin Zhu, Zhihao Lu, Xiaoli Wang, Xinna Zhou, et al.

    Increasing evidence shows that bone marrow stromal cells (BMSCs) have antitumor activities both in vitro and in animal models. Further studies fleshed out the supportive data that the antitumor activity of BMSCs could be markedly enhanced by cytokines such as IL-2 and IFN-β (interferon). However, powerful strategies to activate BMSCs other than by genetically engineering interventions are still required. In this study, new methods of generating antitumor activities of murine marrow-originated MSCs pulsed with homologous tumor-derived exosomes (TEX) were explored to yield potent immune effectors against hepatocellular carcinoma cells in vitro. The results showed that BMSCs pulsed with exosomes and IFN-γ exhibited increased migration ability with a result of 163.22 ± 26.90 versus 129.89 ± 29.28 cells/HP by transwell determination (p < 0.05). The inhibition of homologous hepatocellular carcinoma cells line H22 cells by exosomes pulsed BMSCs was significantly increased by 41.9 % compared with control (p < 0.05), and flow cytometry analysis showed that the cell cycle of H22 cells was arrested in G0/G1 phase. Meanwhile, western blot analysis showed that PCNA protein expression in the supernatant of H22 cells was significantly decreased. This study demonstrated that BMSCs pulsed with TEX could enhance its antitumor activities, which might be regarded as a novel promising antitumor treatment.


  • Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients

    by Lijun Di, Yulin Zhu, Jun Jia, Jing Yu, Gonghong Song, Jie Zhang, Li Che, Huabing Yang, Yan Han, Bo Ma, et al.

    The aim of the study is to explore the safety of cytotoxic T lymphocytes (CTLs) infusion by transfected dendritic cells (DCs) with recombinant adeno-associated virus vector (rAAV) carrying CEA cDNA among advanced cancer patients.


  • Non‐genetic risk factors and predicting efficacy for docetaxel–drug‐induced liver injury among metastatic breast cancer patients

    by Zheng Wang, Xu Liang, Jing Yu, Xiaohui Zheng, Yulin Zhu, Ying Yan, Ningning Dong, Lijun Di, Guohong Song, Xinna Zhou, et al.

    Background and Aim:  Docetaxel has been chosen as one of the most popular anticancer drugs in the treatment of breast cancer for more than a decade. There is increasingly awareness for the occurrence of docetaxel and/or docetaxel–drug‐induced liver injury (DILI), although the underlying mechanism of occurrence and its risk factors remain unclear.Methods:  We conducted a retrospective cohort study to identify non‐genetic risk factors for docetaxel–DILI among 647 metastasis breast cancer patients treated with docetaxel‐containing regimens.Results:  Sixty‐seven (10.36%) patients were diagnosed as docetaxel–DILI. By logistic regression analysis, premenopausal status (odds ratio [OR][95% confidence interval {CI}] = 2.24 [1.30–3.87]), past hepatitis B virus (HBV) infections (OR [95% CI] = 4.23 [1.57–11.42]), liver metastasis (OR [95% CI] = 3.70 [2.16–6.34]). The predominant occurrence of DILI was seen in groups with docetaxel combination regimens. (OR [95% CI] = 2.66 [1.59–4.55]). The potential increasing occurrence of docetaxel–DILI was associated with multiple risk factors in an exposure–response manner (P < 0.001), and patients with more than three risk factors would be exposed to a 36.61‐fold risk of DILI (95% CI = 10.18–131.62). Further analysis by the risk score and area under the receiver–operator characteristic curve (AUC) showed that those four factors contributed to an AUC of 0.7536 (95% CI = 0.70–0.81), with a predictive sensitivity of 74.63% and specificity of 65.17%.Conclusions:  Docetaxel–DILI with a relatively higher incidence should be addressed among metastatic breast cancer patients. Four predominant risk factors, including premenopausal status, past HBV infection, liver metastasis, and docetaxel combination regimens, were potential predicators for DILI.


  • Multicenter clinical study for evaluation of efficacy and safety of transdermal fentanyl matrix patch in treatment of moderate to severe cancer pain in 474 Chinese cancer patients

    by Yu-Lin Zhu, Guo-Hong Song, Duan-Qi Liu, Xi Zhang, Kui-Feng Liu, Ai-Hua Zang, Ying Cheng, Guo-Chun Cao, Jun Liang, Xue-Zhen Ma, et al.

    Objective Although a new matrix formulation fentanyl has been used throughout the world for cancer pain management, few data about its efficacy and clinical outcomes associated with its use in Chinese patients have been obtained. This study aimed to assess the efficacy and safety of the new system in Chinese patients with moderate to severe cancer pain. Methods A total of 474 patients with moderate to severe cancer pain were enrolled in this study and were treated with the new transdermal fentanyl matrix patch (TDF) up to 2 weeks. All the patients were asked to record pain intensity, side effects, quality of life (QOL), adherence and global satisfaction. The initial dose of fentanyl was 25 μg/h titrated with opioid or according to National Comprehensive Cancer Network (NCCN) guidelines. Transdermal fentanyl was changed every three days. Results After 2 weeks. The mean pain intensity of the 459 evaluated patients decreased significantly from 5.63±1.26 to 2.03±1.46 (PP<0.0001). Conclusion The new TDF is effective and safe in treating patients with moderate to severe cancer pain, and can significantly improve the quality of life.


  • Open Access

    MUC1-positive circulating tumor cells and MUC1 protein predict chemotherapeutic efficacy in the treatment of metastatic breast cancer

    by Jian-Ping Cheng, Ying Yan, Xiang-Yi Wang, Yuan-Li Lu, Yan-Hua Yuan, Jun Jia, Jun Ren

    Chemotherapy plays an important role in the treatment of metastatic breast cancer. It is important to monitor chemotherapeutic efficacy, to find a simple and efficient tool to guide treatment, and to predict the efficacy of treatment in a timely and accurate manner. This study aimed to detect mucin-1 (MUC1)– positive circulating tumor cells and MUC1 protein in the peripheral blood of patients with metastatic breast cancer and to investigate their relationship to chemotherapeutic efficacy. MUC1 mRNA was detected in the peripheral blood of 34 patients with newly diagnosed metastatic breast cancer by reverse transcription-polymerase chain reaction. The positive rates of MUC1 mRNA were 88.2% before chemotherapy and 70.6% after chemotherapy, without a significant difference (P = 0.564); MUC1 mRNA expression before chemotherapy had no correlation with treatment effectiveness (P = 0.281). The response rate of MUC1 mRNA-negative patients after first-cycle chemotherapy was significantly higher (P = 0.009) and the progression-free survival (PFS) was clearly longer than those of MUC1 mRNA-positive patients (P = 0.095). MUC1 protein in peripheral blood plasma was detected by an ELISA competitive inhibition assay. The patients with decreased MUC1 protein after chemotherapy had a significantly longer PFS than those with elevated MUC1 protein (P = 0.044). These results indicate that the outcomes of MUC1 mRNA-negative patients after chemotherapy are better than those of MUC1 mRNA-positive patients. In addition, patients with decreased expression of MUC1 protein have a better PFS.


  • Circulating tumor cells in metastatic breast cancer: Monitoring response to chemotherapy and predicting progression-free survival

    by Jian-Ping Cheng, Ying Yan, Xiang-Yi Wang, Yuan-Li Lu, Yan-Hua Yuan, Xiao-Li Wang, Jun Jia, Jun Ren

    The purpose of this study is to explore RT-PCR method to set up the examination platform for detecting circulating tumor cells (CTC) in peripheral blood from metastatic breast cancer patients. The primary endpoint is to find out the correlation of existence of CTC with clinical responses and progression-free survival (PFS).

  • Open Access

    Predominant sarcomatoid carcinoma of the lung concurrent with jejunal metastasis and leukocytosis

    by Jun Jia, Jun Ren, Jin Gu, Lijun Di, Guohong Song

    Sarcomatoid carcinoma is an extremely rare biphasic tumor characterized by a combination of malignant epithelial and mesenchymal cells. Limited data on sarcomatoid carcinoma showed that most cases occurred with advanced local disease and metastasis, and paraneoplastic syndromes were rare. We present the case of a 63-year-old man with lung sarcomatoid carcinoma associated with jejunum metastasis and leukocytosis, and its clinical, macroscopic, and histopathological features. This case emphasizes the importance of recognizing paraneoplastic syndromes and metastasis of sarcomatoid carcinoma at diagnosis.


  • Low correspondence of EGFR mutations in tumor tissue and paired serum of non-small-cell lung cancer patients

    by Guo-Hong Song, Jun Ren, Li-Jian Zhang, Li-Jun Di, Yan-Hua Yuan, Jing Yu, Jun Jia

    Epidermal growth factor receptor (EGFR) mutations are strong determinants of tumor response to EGFR tyrosine kinase inhibitors in non-small-cell lung cancer (NSCLC) patients. The aim of this study was to evaluate the correspondence between EGFR mutations in non-small-cell lung cancer tissues and in circulating DNA. The research was conducted in 50 non-small-cell lung cancer patients who had undergone curative surgery, and in whom both serum and neoplastic tissues were available. Meanwhile sera of 33 cases of advanced NSCLC patients were also analyzed. DNA were extracted from each sample. Mutations of EGFR in exon18-21 were examined by PCR amplification method and direct sequencing. EGFR mutations were detected in 15 (30%) of 50 neoplastic tissue samples, 6 cases were in-frame deletion del E746-A750 in exon19, 9 cases were substitution in exon 21 (all were L858R except one was L861Q), but no mutated DNA resulted in paired serum circulating DNA samples of 50 resectable patients. As the 33 advanced NSCLC patients, EGFR mutations were detected in only 2 serum circulating DNA samples, all were L858R mutation in exon 21. These data indicated that it was difficult to identify EGFR mutations in circulating DNA of NSCLC patients. The use of EGFR mutation in serum as a clinical method for decision making of TKI therapy is unsatisfactory.